GSWM
GRCE

Golden State Wealth Management’s Grace Therapeutics GRCE Stock Holding History

Golden State Wealth Management’s Portfolio GRCE Stock Details GRCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-31
Closed -$116 – 1650
2024
Q4 		$116 Buy
+31
New +$106 ﹤0.01% 1477

Other funds holding GRCE

ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PWM
Palumbo Wealth Management Great Neck, New York $410M AUM 32.56% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Golden State Wealth Management's GRCE Position: Q1 2025 in Review

Golden State Wealth Management sold out of Grace Therapeutics (GRCE) in Q1 2025, closing a stake of 31 shares — an estimated $116 sold.

Golden State Wealth Management first reported a position in GRCE in Q4 2024 and held it in 1 quarter. The position peaked at $116 in Q4 2024. 17 funds tracked by Wall St. Rank hold GRCE as of Q1 2025.

  • Golden State Wealth Management reported no remaining Grace Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Golden State Wealth Management sold 31 Grace Therapeutics shares in Q1 2025, an estimated $116.
  • Golden State Wealth Management first reported a position in Grace Therapeutics in Q4 2024 and held it in 1 quarter.
  • Golden State Wealth Management's Grace Therapeutics position peaked at $116 in Q4 2024.
  • 17 funds tracked by Wall St. Rank held Grace Therapeutics as of Q1 2025.

Based on Golden State Wealth Management's 13F filing for Q1 2025, filed 23 Apr 2025.